Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,417
datasets available to search
ShareScore release 0.9.0
Dataset results
1,417 results for “triple negative breast cancer”
Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Triple Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
ClinicalTrials.gov study NCT06965361. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
ClinicalTrials.gov study NCT06112379. IPD Sharing: YES. Countries: 26. Publications: 1.
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor
ClinicalTrials.gov study NCT05374512. IPD Sharing: YES. Countries: 23. Publications: 1.
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer
ClinicalTrials.gov study NCT01186991. IPD Sharing: Not stated. Countries: 6. Publications: 1.
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
ClinicalTrials.gov study NCT04454437. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer
ClinicalTrials.gov study NCT01653561. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
ClinicalTrials.gov study NCT01426880. IPD Sharing: Not stated. Countries: 1. Publications: 4.
PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer
ClinicalTrials.gov study NCT02423603. IPD Sharing: Not stated. Countries: 6. Publications: 1.
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
ClinicalTrials.gov study NCT05203445. IPD Sharing: YES. Countries: 1. Publications: 0.
Exercise in Triple- Negative Breast Cancer
ClinicalTrials.gov study NCT06672120. IPD Sharing: NO. Countries: 1. Publications: 12.
Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
ClinicalTrials.gov study NCT02474173. IPD Sharing: Not stated. Countries: 1. Publications: 1.
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
ClinicalTrials.gov study NCT04360941. IPD Sharing: NO. Countries: 1. Publications: 40.
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
ClinicalTrials.gov study NCT05929768. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)
ClinicalTrials.gov study NCT02622074. IPD Sharing: YES. Countries: 0. Publications: 3.
Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer
ClinicalTrials.gov study NCT03735082. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer
ClinicalTrials.gov study NCT02685059. IPD Sharing: NO. Countries: 1. Publications: 3.
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
ClinicalTrials.gov study NCT04584112. IPD Sharing: YES. Countries: 8. Publications: 1.
Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer
ClinicalTrials.gov study NCT06938724. IPD Sharing: NO. Countries: 1. Publications: 2.
PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy
ClinicalTrials.gov study NCT02448576. IPD Sharing: Not stated. Countries: 1. Publications: 17.
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
ClinicalTrials.gov study NCT03911973. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.